These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Oral ganciclovir approved for CMV.
    Journal: Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362347.
    Abstract:
    The Food and Drug Administration (FDA) approved the oral form of ganciclovir for maintenance treatment of cytomegalovirus (CMV) retinitis, and it is believed oral ganciclovir will be approved soon for primary prophylaxis of CMV retinitis. The IV form has too many toxicities and is too inconvenient for preventive use. Oral ganciclovir has the same toxicity profile as the IV form. Syntex Corporation, the manufacturer of ganciclovir, has instituted a protocol to allow HIV-positive persons with low CD4 counts to use oral ganciclovir for prophylaxis. The protocol distributes the drug at no cost to the individual. Approval is being sought to use oral ganciclovir to prevent CMV symptoms. Information can be obtained by calling Syntex at (800)569-4630.
    [Abstract] [Full Text] [Related] [New Search]